Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/19617Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Nikas, S. N. | en |
| dc.contributor.author | Drosos, A. A. | en |
| dc.date.accessioned | 2015-11-24T19:00:55Z | - |
| dc.date.available | 2015-11-24T19:00:55Z | - |
| dc.identifier.issn | 1472-4472 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19617 | - |
| dc.rights | Default Licence | - |
| dc.subject | Animals | en |
| dc.subject | *Anti-Inflammatory Agents, Non-Steroidal/chemistry/pharmacokinetics/therapeutic | en |
| dc.subject | use | en |
| dc.subject | *Carrier Proteins/chemistry/pharmacokinetics/therapeutic use | en |
| dc.subject | Clinical Trials, Phase I as Topic | en |
| dc.subject | Clinical Trials, Phase II as Topic | en |
| dc.subject | Crohn Disease/*drug therapy | en |
| dc.subject | Half-Life | en |
| dc.subject | Humans | en |
| dc.subject | Psoriasis/*drug therapy | en |
| dc.subject | *Receptors, Tumor Necrosis Factor | en |
| dc.subject | Receptors, Tumor Necrosis Factor, Type I | en |
| dc.subject | Structure-Activity Relationship | en |
| dc.subject | Treatment Outcome | en |
| dc.subject | Tumor Necrosis Factor Decoy Receptors | en |
| dc.title | Onercept. Serono | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/14758777 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2003 | - |
| heal.abstract | Onercept is a recombinant human soluble p55 tumor necrosis factor binding protein under development by Serono for the potential treatment of a number of disorders, including Crohn's disease, psoriasis and psoriatic arthritis. In March 2002, phase II trials were ongoing for these indications, and in February 2003, Serono expected phase III trials in psoriatic arthritis to commence in the second half of 2003. | en |
| heal.journalName | Curr Opin Investig Drugs | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
